Witnessing the stock’s movement on the chart, on Wednesday, Monte Rosa Therapeutics Inc (NASDAQ: GLUE) set off with pace as it heaved 9.41% to $16.86, before settling in for the price of $15.41 at the close. Taking a more long-term approach, GLUE posted a 52-week range of $3.50-$16.66.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -41.09%. Meanwhile, its Annual Earning per share during the time was -41.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 75.92%. This publicly-traded company’s shares outstanding now amounts to $61.79 million, simultaneously with a float of $42.21 million. The organization now has a market capitalization sitting at $1.10 billion. At the time of writing, stock’s 50-day Moving Average stood at $11.59, while the 200-day Moving Average is $6.67.
Monte Rosa Therapeutics Inc (GLUE) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Monte Rosa Therapeutics Inc’s current insider ownership accounts for 35.18%, in contrast to 70.72% institutional ownership. According to the most recent insider trade that took place on Jun 03 ’25, this organization’s Principal Accounting Officer sold 2,062 shares at the rate of 4.45, making the entire transaction reach 9,174 in total value, affecting insider ownership by 23,732. Preceding that transaction, on Mar 24 ’25, Company’s Director bought 10,000 for 5.84, making the whole transaction’s value amount to 58,383. This particular insider is now the holder of 10,000 in total.
Monte Rosa Therapeutics Inc (GLUE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
Monte Rosa Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 75.92% and is forecasted to reach -1.44 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -10.87% through the next 5 years, which can be compared against the -41.09% growth it accomplished over the previous five years trading on the market.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Trading Performance Indicators
Let’s observe the current performance indicators for Monte Rosa Therapeutics Inc (GLUE). It’s Quick Ratio in the last reported quarter now stands at 6.54. Alongside those numbers, its PE Ratio stands at $55.21, and its Beta score is 1.61. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.05. Similarly, its price to free cash flow for trailing twelve months is now 7.57.
In the same vein, GLUE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.31, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -1.44 at the market close of one year from today.
Technical Analysis of Monte Rosa Therapeutics Inc (GLUE)
Going through the that latest performance of [Monte Rosa Therapeutics Inc, GLUE]. Its last 5-days volume of 0.72 million was inferior to the volume of 0.85 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 78.66% While, its Average True Range was 72.90.
Raw Stochastic average of Monte Rosa Therapeutics Inc (GLUE) in the period of the previous 100 days is set at 98.99%, which indicates a major rise in contrast to 96.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.95 that was higher than 0.59 volatility it exhibited in the past 100-days period.
